Determining the conditions for robust acidoCEST MRI to measure extracellular pH in tumors in vivo
Rohan S. Virgincar1, Kai H. Barck1, Mary Ann Go2, Geoffrey Del Rosario2, Shang-Fan Yu2, ManKin Choy1, Alvin Gogineni1, Justin Elstrott1, Herman S. Gill1, Jan Marik1, Genee Lee2, Mark D. Pagel3, Alex de Crespigny4, Teemu T. Junttila5, Christoph Spiess6, Robby M. Weimer1, and Luke Xie1
1Biomedical Imaging, Genentech, South San Francisco, CA, United States, 2Translational Oncology, Genentech, South San Francisco, CA, United States, 3Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States, 4Early Clinical Development, Genentech, South San Francisco, CA, United States, 5In Vivo Pharmacology, Genentech, South San Francisco, CA, United States, 6Antibody Engineering, Genentech, South San Francisco, CA, United States
AcidoCEST MRI is a promising technique to directly measure extracellular pH in vivo and is well-suited to imaging tumors, which can exhibit acidosis. However, few studies have demonstrated the conditions and the minimum contrast agent concentrations needed for robust acidoCEST MRI. In this study, we employed micro-CT to determine the uptake of iopamidol in tumors with intratumoral and intravenous delivery of isovue-370, estimated the accuracy of pH measured by MRI vs. a pH meter, demonstrated the minimum iopamidol concentration required for acidoCEST MRI, and reported pH measurements in different tumor xenograft models.
This abstract and the presentation materials are available to members only;
a login is required.